Deprescribing in Patients of Hypothyroidism Results in Better Health Outcome: A Case Series

  • Prashant Mishra Department of Pharmacology, Armed Forces Medical College, Pune-40, India.
  • Shashikant Bhargava Department of Pharmacology, Clinical Pharmacologist, RML Hospital, New Delhi-01, India.
Keywords: Hypothyroidism; Levothyroxine; Deprescribing; Drug-Drug Interaction


Appropriate levothyroxine (LT4) dosing is essential in hypothyroid patients to maintain biochemical and clinical euthyroidism, but achieving appropriate plasma concentration of LT4 can be complicated by numerous disease states, foods, supplements, and commonly prescribed medications such as calcium supplements, pantoprazole etc. that potentially interfere with intestinal LT4 absorption. About one-third of treated patients are not receiving adequate treatment, leading to decreased quality of life, increased morbidity, and even increased mortality. Hypothyroid patients treated with LT4 must be careful to avoid concomitant ingestion of such medicines or optimal gap must be ensured between ingestions to prevent drug-drug interactions and reduce absorption of LT4. We describe two such real life cases managed in our clinical pharmacology consultation facility to highlight the importance of systematically evaluating the drug-drug interactions of levothyroxine with commonly used concomitant medications and how deprescribing of the same can result in attainment of optimum thyroid replacement with lesser doses of LT4 with better patient outcome.